The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries

Aims Evaluate the safety and efficacy of once‐daily insulin detemir initiated in routine clinical practice in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycaemic agents (OHAs). Methods This large observational study was conducted in 10 countries. Adverse event data...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2012-12, Vol.14 (12), p.1129-1136
Main Authors: Khunti, K., Caputo, S., Damci, T., Dzida, G. J., Ji, Q., Kaiser, M., Karnieli, E., Liebl, A., Ligthelm, R. J., Nazeri, A., Orozco-Beltran, D., Pan, C., Ross, S. A., Svendsen, A. L., Vora, J., Yale, J.-F., Meneghini, L. F.
Format: Article
Language:English
Subjects:
Aged
basal insulin
Blood Glucose - metabolism
Body Mass Index
Canada - epidemiology
China - epidemiology
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - epidemiology
Drug Administration Schedule
Drug Therapy, Combination
Europe - epidemiology
Female
Glycated Hemoglobin A - metabolism
HbA1c
Humans
hypoglycaemia
Hypoglycemic Agents - administration & dosage
Insulin - analogs & derivatives
Insulin - therapeutic use
Insulin Detemir
Insulin, Long-Acting - administration & dosage
Male
metformin
Middle Aged
oral hypoglycaemic agent
sulphonylurea
Treatment Outcome
type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims Evaluate the safety and efficacy of once‐daily insulin detemir initiated in routine clinical practice in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycaemic agents (OHAs). Methods This large observational study was conducted in 10 countries. Adverse event data (including hypoglycaemia) and glycaemic control were recorded before and 24 weeks following insulin initiation while patients continued routine clinical management. Results In this study, 17 374 patients (53% male) were included. Mean pre‐insulin values (±s.d.) were: age 62 ± 12 years; body mass index (BMI) 29.3 ± 5.4 kg/m2; diabetes duration 10 ± 7 years; haemoglobin A1c (HbA1c) 8.9 ± 1.6%. During the study, 27 patients experienced serious adverse drug reaction, severe hypoglycaemic events or both; and there were 31 episodes of severe hypoglycaemia in 21 patients. After 24 weeks, HbA1c was 7.5 ± 1.2% (change of −1.3%; p 
ISSN:1462-8902
1463-1326
DOI:10.1111/j.1463-1326.2012.01665.x